Mirum Pharmaceuticals To Highlight LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) will present data from its LIVMARLI® (maralixibat) oral solution studies at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) annual meeting. The data includes 15 abstracts from ALGS and PFIC programs, with the primary analysis from the MARCH study being awarded the Gerard Odell Prize for Excellence in Pediatric Hepatology Research.
September 26, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals' upcoming presentation of LIVMARLI data at the NASPGHAN annual meeting could potentially boost investor confidence in the company's research and development capabilities.
The presentation of LIVMARLI data, including the award-winning MARCH study, at a prestigious event like the NASPGHAN annual meeting, could be seen as a validation of Mirum Pharmaceuticals' research and development efforts. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100